409 Approximately 5% of users experience manifestations such as rash, gastrointestinal complaints, and hypersensitivity reactions
Data from the EFFISAYIL program show spesolimab provides: Sustained reduction in flare frequency over 3 years ~75% of patients remaining flare-free Stable safety profile with no new signals Given the severity and unpredictability of GPP, these findings reinforce the value of targeted IL-36 inhibition for durable disease suppression
93 In contrast, markers of mineral metabolismincluding 25-hydroxyvitamin D, bone-specific alkaline phosphatase (BALP), and PTHremain largely stable over the long term, 94 suggesting that VSG-mediated skeletal remodeling occurs independently of traditional calciumphosphorus regulatory pathways
If you use them without hitting protein targets, youll accelerate muscle loss and look worse even at a lower weight
Data analysis: Data processing was performed using SCIEX OS Software 1.5
Matsushita M, Shichiri M, Imai T, Iwashina M, Tanaka H, Takasu N, Hirata Y